Alzamend Neuro, Inc.
ALZN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ALZN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALZN
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing two product candidates, AL001 and ALZN002, for Alzheimer's disease and related psychiatric indications, with no approved products or revenue and a limited cash runway.
Key risk: Cash runway insufficient
BioSniper Score
Based on 5 of 6 signals
Financial data as of Apr 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 1 catalyst for Alzamend Neuro, Inc..
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing two product candidates, AL001 and ALZN002, for Alzheimer's disease and related psychiatric indications, with no approved products or revenue and a limited cash runway.
- Alzamend Neuro is a clinical-stage biopharmaceutical company with no approved products or revenue [sec_mda · as of 2026-07-22].
- As of April 30, 2026, the company had $711,000 in cash and cash equivalents, which management believes is insufficient to fund operations for the next twelve months [sec_mda · as of 2026-07-22].
- The company is developing AL001 for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD, and ALZN002 for mild to moderate dementia of the Alzheimer's type [sec_mda · as of 2026-07-22].
- Alzamend has not initiated or completed a pivotal clinical trial, obtained marketing approval, or manufactured a commercial-scale product [sec_mda · as of 2026-07-22].
- The company's near-term prospects depend entirely on the successful development, FDA approval, and commercialization of AL001 or ALZN002 [sec_mda · as of 2026-07-22].
What works
- Alzamend has two product candidates in clinical development targeting large unmet medical needs (Alzheimer's disease and related psychiatric conditions) [sec_mda · as of 2026-07-22].
- The company has initiated clinical trials for both AL001 and ALZN002, indicating progress toward potential proof-of-concept data [sec_mda · as of 2026-07-22].
What to weigh
- Alzamend has a very limited cash position ($711,000 as of April 30, 2026) and expects it will not be sufficient to fund operations for the next twelve months [sec_mda · as of 2026-07-22].
- The company has no approved products, no revenue, and has never completed a pivotal clinical trial or obtained marketing approval [sec_mda · as of 2026-07-22].
- There is a high rate of failure for drug candidates in clinical trials, and Alzamend may face significant setbacks similar to other biotech companies [sec_mda · as of 2026-07-22].
- Alzamend will need substantial additional funding to complete development and seek FDA approval, and such funding may not be available on reasonable terms [sec_mda · as of 2026-07-22].
From the filings
Quoted directly from source documents.
Cash position as of April 30, 2026
“As of April 30, 2026, we had $711,000 in cash and cash equivalents.”
SEC MD&A · July 22, 2026
Cash runway concern
“Based on our current operating plan, we believe that this funding will not be sufficient to fund our operations for the next twelve months.”
SEC MD&A · July 22, 2026
No approved products or revenue
“We are a clinical-stage biopharmaceutical company. We have initiated clinical trials for our AL001 and ALZN002 programs. To date, we have not initiated or completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization.”
SEC MD&A · July 22, 2026
Dependence on product candidates
“Our near-term prospects, including our ability to finance our company and to enter into strategic collaborations and, ultimately, to generate revenue, are directly dependent upon the successful development, FDA approval and commercialization of AL001 or ALZN002.”
SEC MD&A · July 22, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · al001 — Phase 2 Readout: al001 — Topline results from the Phase 2 clinical trial for AL001 are expected, which will be a key data point for the program's future.
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Cash of $0.7M as of 2026-04-30 is not expected to fund operations for the next twelve months [sec_mda · as of 2026-07-22].
- No approved products or revenue — Company has no approved products, no revenue, and has never completed a pivotal trial [sec_mda · as of 2026-07-22].
- Clinical trial failure risk — High rate of failure for drug candidates in clinical trials; setbacks are common even after promising early results [sec_mda · as of 2026-07-22].
- Dilutive financing needed — Additional capital may be raised through stock sales, causing substantial dilution to existing stockholders [sec_mda · as of 2026-07-22].
What to watch
- Phase 2 topline data for AL001 expected by 2026-12-31 [catalyst].
- Ability to secure additional financing to continue operations beyond the current cash runway [sec_mda · as of 2026-07-22].
- Enrollment and progress in the Phase I/IIA trial for ALZN002 [sec_mda · as of 2026-07-22].
- Any regulatory interactions or FDA feedback on AL001 or ALZN002 [sec_mda · as of 2026-07-22].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Alzamend Neuro, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alzamend Neuro, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.84
Lead: Phase 1/Phase 2
2 candidates
1 upcoming, next in ~123d
1 buy · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$105K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 45,680 | $48K |
| vanguard fiduciary trust co | 21,020 | $22K |
| morgan stanley | 18,000 | $19K |
| vanguard capital management llc | 8,800 | $9K |
| citigroup inc | 5,231 | $6K |
| blackrock, inc. | 437 | $463 |
| caitong international asset management co., ltd | 4 | $4 |
| harbor investment advisory, llc | 1 | $1 |
Short Interest
as of May 20, 2026- % of float
- 5.4%
- Days to cover
- 2.4
- Shares short
- 204,743
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALZN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Alzamend Neuro, Inc.?
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing two product candidates, AL001 and ALZN002, for Alzheimer's disease and related psychiatric indications, with no approved products or revenue and a limited cash runway.
What is Alzamend Neuro, Inc.'s lead drug candidate?
Alzamend Neuro, Inc.'s most advanced tracked candidate is AL001 (Phase 1) for Pharmacokinetics; Bipolar I Disorder.
What is Alzamend Neuro, Inc.'s next catalyst?
Alzamend Neuro, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: al001" — expected December 31, 2026.
Who is the CEO of Alzamend Neuro, Inc.?
Mr. Stephan Jackman is the chief executive officer of Alzamend Neuro, Inc. (ALZN).
Where is Alzamend Neuro, Inc. headquartered?
Alzamend Neuro, Inc. (ALZN) is headquartered in Atlanta, GA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.